Sushi Recall as FDA Issues Highest Risk Warning
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A recall of sushi products has been issued the highest risk classification by the U.S. Food and Drug Administration (FDA).
Hy-Vee, a supermarket chain headquartered in Iowa, issued a voluntary recall for a range of sushi products on June 5 because of possible listeria contamination. The FDA subsequently issued its Class 1 risk classification on June 25.
Newsweek contacted Hy-Vee for comment by email outside regular working hours.
Stock image. A recall of numerous Hy-Vee sushi products has been issued a Class 1 risk classification by the FDA.
Stock image. A recall of numerous Hy-Vee sushi products has been issued a Class 1 risk classification by the FDA.
Frank Duenzl/picture-alliance/dpa/AP
Why It Matters
A Class I risk classification represents "a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death," according to the FDA.
Listeria contamination may lead to a range of symptoms in infected individuals. For those experiencing less severe infections, symptoms include fever, muscle aches, nausea, vomiting and diarrhea, which often last between one and three days, the FDA said.
For more severe and potentially life-threatening infections, symptoms may include headaches, stiff neck, confusion, loss of balance and convulsions. Severe infections are particularly dangerous for newborns, adults over age 65 and those with weakened immune systems.
What To Know
The affected products were sent to Hy-Vee retail locations throughout the Midwest, according to the FDA. The affected products include:
Crispy Shrimp Roll 10Pc - 122.5 cases - code: 02-86792-00000
Crunchy Shrimp Roll - 122.5 cases - code: 02-86793-00000
Red Dragon Roll - 122.5 cases - code: 02-86811-00000
Rock N Roll Shrimp 10Ct - 122.5 cases - code: 02-86813-00000
Duo Spicy Calif Shrimp 10Pc - 122.5 cases - code: 02-86832-00000
Duo Spicy Veg Shrimp 10Pc - 122.5 cases - code: 02-86835-00000
Duo Crunchy Calif Shrimp 10Pc - 122.5 cases - code: 02-86840-00000
Duo Crispy Calif Shrimp 10Pc - 122.5 cases - code: 02-86841-00000
Duo Crunchy Veg Shrimp 10Pc - 122.5 cases - code: 02-86846-00000
Duo Crispy Veg Shrimp 10Pc - 122.5 cases - code: 02-86847-00000
Spicy Shrimp Poke Bowl - 122.5 cases - code: 02-86882-00000
What People Are Saying
Haley F. Oliver, a professor of food science at Purdue University, previously told Newsweek: "Listeria monocytogenes is a common microorganism that can be found in the natural environment, for example in soil. There are many factors that determine if someone gets listeriosis—a listeria infection. In most instances, an immunocompromised person, so young, old, pregnant or otherwise immunocompromised, must eat contaminated food. The number of bacteria resulting in infection and the amount of time before illness varies considerably. Symptoms vary among people but can include fever, flu-like symptoms, headache, stiff neck, confusion and loss of balance."
Mary O'Riordan, a professor of microbiology and immunology at the University of Michigan Medical School, previously told Newsweek: "Listeria has an unusual capacity to grow at refrigerated temperatures. Although the bacterium can contaminate many types of food, cheeses or deli meats that are kept in cold storage for long periods in stores or at home, are a place where Listeria can keep growing.
"Early symptoms of listeria infection look similar to other common foodborne infections, including fever, diarrhea and vomiting, so it's often not diagnosed right away. Unfortunately, sometimes listeria can spread into the brain and cause more serious illness, like meningitis. In those cases, if people experience headache, stiff neck or confusion, they should seek urgent medical attention."
Cleveland Clinic, on its website: "Listeria is a bacterial infection that's more dangerous during pregnancy. It can cause pregnancy loss, lifelong illness in your child and newborn death. It causes flu-like and digestive symptoms. Avoiding foods like deli meats, soft cheeses and unpasteurized milk can reduce your risk."
What Happens Next
The recall is listed as ongoing, according to the FDA.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
FDA approves Gilead's twice-yearly injectable Yeztugo for PrEP
The US Food and Drug Administration (FDA) has approved Gilead Science's Yeztugo for the prevention of human immunodeficiency virus (HIV) infection. This is the first and only FDA-approved HIV pre-exposure prophylaxis (PrEP) option offering six months of protection. The approval was based on the Phase III PURPOSE 1 and PURPOSE 2 trials, which showed that more than 99% of participants remained HIV-negative on the twice-yearly injectable therapy. Yetzugo is a long-acting HIV-1 capsid inhibitor that reduces the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg. Yeztugo will compete with Gilead's own oral PrEP therapies Truvada and Descovy, as well as ViiV Healthcare's Apretude, the only other injectable PrEP therapy available in the US. However, Apretude requires more frequent dosing than Yetzugo, as it is typically administered once every two months. The approval of Yeztugo is a momentous step in improving PrEP options available for people vulnerable to contracting HIV. Currently, the majority of PrEP therapies require daily oral administration. Key opinion leaders (KOLs) previously interviewed by leading data and analytics company GlobalData noted that there is often a psychosocial burden when taking daily PrEP due to stigma, and patients have concerns about others discovering their medication or adherence challenges. Yeztugo could address these key issues. However, KOLs noted that the cost of the drug could be a major barrier to uptake. Gilead has announced the US price of Yeztugo for PrEP at $28,218 per year for each patient. KOLs expressed doubts about whether insurance companies will cover the cost of this drug since generic versions of oral PrEP medications are widely available and much less expensive. Additionally, this situation may be exacerbated by the HIV funding cuts that have been proposed by US President Donald Trump's administration. Furthermore, PrEP usage has not been maximised across the US thus far. According to GlobalData epidemiologists, 437,425 people were on PrEP in the US in 2022, but this figure had the potential to be much higher. In the same year, only 36% of people in the US who met the Centers for Disease Control and Prevention's (CDC) eligibility criteria for PrEP were prescribed a form of PrEP. CDC data shows that vulnerable populations in the US are not yet using PrEP at rates that could end the transmission of the virus at the population level, with particular gaps for women, Black/African American, and Hispanic/Latino people. Increasing awareness and access will be an important element of reducing HIV through PrEP use and maximising Yetzugo's sales. Yeztugo is likely to be approved in other countries shortly, as Gilead has filed for regulatory approval in several markets, including the European Medicines Agency, where it is under accelerated review. "FDA approves Gilead's twice-yearly injectable Yeztugo for PrEP" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Miami Herald
2 hours ago
- Miami Herald
The Connection Between Alcohol Use and Psychiatric Conditions
Earn Continuing Education credits and learn about the complex interplay between alcohol use disorder (AUD) and common co-occurring psychiatric conditions, including bipolar disorder, major depressive disorder, and generalized anxiety disorder. ROCKVILLE, MD / ACCESS Newswire / June 26, 2025 / "Providers Clinical Support System - Medications for Alcohol Use Disorder" (PCSS-MAUD) offers new, free training on alcohol use disorder (AUD) and and common co-occurring psychiatric conditions, including bipolar disorder, major depressive disorder, and generalized anxiety disorder. Learners will gain an understanding of how these conditions interact, diagnostic tools and strategies for screening and diagnosis, and evidence-based treatment approaches. An on-demand, interactive module, featuring two national experts, combines theoretical knowledge with practical approaches, ensuring learners are equipped to address these co-occurring conditions in their clinical practice. This online module allows learners to earn 2 continuing education credits upon completion. Alcohol is one of the most used substances in the United States. According to the National Survey on Drug Use and Health, 28.9 million people 12 and older had alcohol use disorder (AUD) in 2023. Many individuals with AUD also have a co-occurring psychiatric condition such as major depressive disorder, anxiety, or bipolar disorder. Estimates suggest that the prevalence of AUD among persons with anxiety disorders and/or mood disorders range from 20-40%. Effectively treating both conditions is essential to supporting recovery. PCSS-MAUD is a national program that provides free training, guidance, and mentoring on the prevention, diagnosis, and treatment of AUD. The program aims to enhance the capacity of physicians, nurse practitioners, physician associates/physician assistants, nurses, pharmacists, substance use disorder counseling professionals, and other health care providers to treat individuals with AUD, including the use of Food and Drug Administration (FDA)-approved MAUD. Learn more and register for this training HERE. Contact Information Amanda Rogalski Marketing Directoraarogalski@ Stephanie Swanson, MPH Director, Federal Programssswanson@ SOURCE: PCSS-MAUD press release
Politico
2 hours ago
- Politico
Kennedy's vaccine panel votes to remove preservative long targeted by activists
ATLANTA — A panel of vaccine advisers selected by Health Secretary Robert F. Kennedy Jr. voted Thursday to recommend that no one get a flu vaccine that contains thimerosal — a preservative that has long been a target of the anti-vaccine movement and Kennedy himself. Five members voted to recommend that no children, pregnant women, or adult get any flu vaccine with thimerosal. If the CDC adopts the recommendation, it will mark one of the first major changes in federal vaccine guidance and access as Kennedy embarks on his goal of remaking immunization policy in his image. 'The risk from influenza is so much greater than the non-existent, as far as we know, risk from thimerosal,' said Dr. Cody Meissner, the only panel member who voted no. 'I would hate for a person not to receive the influenza vaccine because the only available preparation is with thimerosal.' The CDC director usually needs to endorse the recommendations before they are official. But Kennedy will likely be the one to endorse these recommendations because there is currently no CDC director or acting director. The decision came after a presentation from Lyn Redwood, a former president of the Kennedy-founded anti-vaccine group Children's Health Defense, who identified herself as a 'private citizen.' The Washington Post reported Wednesday that Kennedy had hired Redwood to work in the CDC's vaccine safety office. The HHS directory lists Redwood as an 'expert' in the Office of the Assistant Secretary for Health. Department spokespeople and Redwood didn't respond to requests for comment on Redwood's role. Redwood's presentation largely argued that thimerosal, a preservative that has been used in vaccines since the 1930s, should be removed from the products because of safety concerns. The CDC website says that there is 'no evidence of harm caused by the low doses of thimerosal in vaccines, except for minor reactions like redness and swelling at the injection site.' A CDC background document for members of the Advisory Committee on Immunization Practices, posted by the agency on Tuesday and later removed from its website, also diverges from Redwood's conclusion, arguing there is overwhelming evidence that thimerosal-containing vaccines do not cause neurological problems. ACIP member Dr. Robert Malone said the document was removed because 'it was not authorized by the office of the secretary.' Redwood's presentation argued there is evidence that thimerosal can cause serious complications, especially for pregnant women. 'The fact that thimerosal from vaccines has been documented to raise blood mercury levels over known thresholds where developmental effects have been documented to occur during the first few months of life, means that particular 'windows of vulnerability' may have been breached,' Redwood said. Thimerosal continues to be used as a preservative in multi-dose vaccine vials to inhibit germ growth, but the vast majority of FDA-licensed flu vaccines are already thimerosal-free — 96 percent of all flu vaccines in the U.S. last season didn't contain the preservative, according to the CDC document removed from the website. It was largely removed from childhood vaccines in 2001, and several pediatric products — including the measles, mumps and rubella and varicella shots — never included the ingredient. In 1999, the FDA and CDC announced plans to work with manufacturers to reduce or remove thimerosal from vaccines as a precautionary measure. But the move was a precautionary measure, and further research has identified no link between the ingredient and neurological defects. Several ACIP members agreed with Redwood, including committee Chair Martin Kulldorff, who argued that while the level of thimerosal in vaccines may be safe, it could contribute to high cumulative mercury exposure. But Meissner, a pediatrics professor at Dartmouth College's medical school, pushed back strongly against Redwood's assertion. 'I'm not quite sure how to respond to this presentation,' Meissner said. He went on to note that thimerosal is metabolized into ethylmercury and thiosalicylate, not methylmercury, which is found in fish and shellfish and is highly toxic to humans. 'Ethylmercury is excreted much more quickly from the body, and is not associated with the high neurotoxicity that methylmercury has,' Meissner noted. 'Of all the issues that I think ACIP needs to focus on, this is not a big issue,' he added. Many public health experts on the call also pushed back. Jason Goldman of the American College of Physicians asked whether the committee would get an 'actual CDC presentation done by staff, scientists, physicians and those who are subject matter experts with accurate, peer-reviewed scientific data or the ability for the committee to review [the data]' or if they would just hear 'layperson presentations.' Separately, the panel also recommended the updated influenza vaccine for the upcoming fall and winter season. Six members voted to approve, while Vicky Pebsworth, a public health scientist and nurse who's served on the board of an anti-vaccine group, abstained. Members of the press were not allowed to leave the press area, largely preventing them from speaking with the members of the committee. Kulldorff declined to answer questions following the meeting. 'This committee strongly supports the use of vaccines and other counter measures predicated on evidence-based medicine, including rigorous evaluation and expansive credible scientific data for both safety and efficacy,' the committee said in a statement after the meeting concluded. 'All stakeholders, including healthcare providers, parents, children, schools, nursing homes, insurance providers, public health agencies, manufacturers and the rare few who may be harmed by recommended interventions need to have understandable, digestible, scientifically correct information.' The CDC's vaccine advisory committee may consider at its next meeting a proposal to advise against giving a combination shot against measles and chickenpox to children under 4, Kulldorff said Thursday after delivering a presentation on the product. Under the current childhood immunization schedule, the CDC recommends that children receive two doses of the measles, mumps and rubella vaccine and the varicella vaccine — the first between 12 and 15 months and the second between 4 and 6 years of age. An MMR-chickenpox combination vaccine, known as MMRV, may be used, but the agency advises that the first dose be administered as two separate shots. ACIP updated its recommendation in 2009 to recommend separate MMR and varicella vaccinations for younger children due to an increased risk of febrile seizures in children under 2 who received the combination shot compared with those who got the two distinct vaccines. Fever-induced seizures are common in young children — the CDC estimates the risk at 5 percent — but don't cause permanent harm. 'A proposed recommendation — we're not going to vote on that this time, but possibly at the next meeting — could be that, as there exists a safer, equally effective alternative, the MMRV vaccine should not be administered to children under the age of 47 months,' Kulldorff said.
